VANCOUVER, BC – September 7, 2021 – Izotropic Corporation (“Izotropic” or the “Company”) (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) a Company commercializing a dedicated Breast CT (computed tomography) imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers, announced today that it has engaged Oak Hill Financial to provide financial marketing services and Mr. Tyler Muir of TMM Capital Advisory to provide social media and communications services.
Oak Hill Financial is a leading Canadian marketing and distribution firm, focused on IIROC retail brokerage networks, servicing both asset managers and public companies. Oak Hill Financial’s experienced team of former asset management wholesalers, research analysts and capital market professionals specializes in building credibility for their clients to a network of over 10,000 Canadian IIROC retail brokers and over 300 North American funds.
Under the terms of the aforementioned agreements, Oak Hill Financial has been engaged for an initial three (3) month term with an option for renewal and a monthly fee of $10,000.00. The Company has issued Oak Hill Financial 100,000 stock options at an exercise price of $0.84 for an 18-month term. The options vest on a quarterly basis from the date of this announcement. If the agreement is terminated for any reason, Oak Hill Financial shall have 60 days to exercise all vested options, after which point, they are cancelled.
Mr. Tyler Muir has been engaged for an initial six (6) month term with an option for renewal and a monthly fee of $3,500.00. The Company has issued Mr. Tyler Muir of TMM Capital Advisory 100,000 stock options at an exercise price of $0.84 for a 2-year term. The stock options vest immediately.
The Company has cancelled 400,000 stock options previously issued to consultants that are no longer engaged by the Company.
ON BEHALF OF THE COMPANY
Dr. John McGraw, CEO
For investor relations inquiries, contact:
James Berard, Investor Relations Manager
Toll Free: 1-833-IZOCORP ext.1
About Izotropic Corporation
Izotropic Corporation is the only publicly traded company commercializing a dedicated breast CT imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers. To expedite patient and provider access to IzoView, Izotropic’s initial clinical study intends to demonstrate superior performance of diagnostic breast CT imaging over diagnostic mammography procedures and will initiate in Q2 2022. In follow-on clinical studies, Izotropic intends to validate platform applications including breast screening in radiology, treatment planning and monitoring in surgical oncology, and breast reconstruction and implant monitoring in plastic and reconstructive surgery.
IzoView produces high resolution breast images in true 3D and is ideal for imaging patients with dense breast tissue. A single 10 second scan acquires approximately 500 images, without painful breast compression or continual technician breast handling, providing a more comfortable patient experience with low radiation dose levels.
In addition to improved detection capabilities, Izotropic anticipates IzoView’s higher resolution 3D images could provide more accurate margin analysis (viewing edges of a tumor), lesion characterization (determining the qualities of an abnormality), and higher spatial resolution (the imaging ability to differentiate between internal breast structures). More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com
This document may contain statements that are “Forward-Looking Statements,” which are based upon the current estimates, assumptions, projections and expectations of the Company’s management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company’s activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.Neither the Company nor its shareholders, officers, and consultants, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind.